You are here: Home » News-CM » Companies » News
Business Standard

Dr Reddy's Laboratories gets USFDA approval to launch Doxorubicin Hydrochloride Liposome Injection

Capital Market 

In United States market

Dr Reddy's Laboratories announced that it has received approval from USFDA to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil, for intravenous use, in the United States market.

Powered by Capital Market - Live News

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Dr Reddy's Laboratories gets USFDA approval to launch Doxorubicin Hydrochloride Liposome Injection

In United States market

In United States market

Dr Reddy's Laboratories announced that it has received approval from USFDA to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil, for intravenous use, in the United States market.

Powered by Capital Market - Live News

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Dr Reddy's Laboratories gets USFDA approval to launch Doxorubicin Hydrochloride Liposome Injection

In United States market

Dr Reddy's Laboratories announced that it has received approval from USFDA to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil, for intravenous use, in the United States market.

Powered by Capital Market - Live News

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22